Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904652816> ?p ?o ?g. }
- W2904652816 endingPage "606" @default.
- W2904652816 startingPage "595" @default.
- W2904652816 abstract "Many novel vaginal/rectal microbicide formulations failed clinically due to safety concerns, indicating the need for the early investigation of lead microbicide formulations. In this study, the preclinical safety of an HIV-1 gp120 and mannose responsive microbicide delivery system (MRP) is evaluated in C57BL/6 mice. MRP was engineered through the layer-by-layer coating of calcium carbonate (CaCO3) with Canavalia ensiformis lectin (Con A) and glycogen. MRP mean particle diameter and zeta potential were 857.8 ± 93.1 nm and 2.37 ± 4.12 mV, respectively. Tenofovir (TFV) encapsulation and loading efficiencies in MRP were 70.1% and 16.3% w/w, respectively. When exposed to HIV-1 rgp120 (25 μg/mL), MRP released a significant amount of TFV (∼5-fold higher) in vaginal and seminal fluid mixture compared to the control (pre-exposure) level (∼59 μg/mL) in vaginal fluid alone. Unlike the positive control treated groups (e.g., nonoxynol-9), no significant histological damages and CD45+ cells infiltration were observed in the vaginal and major reproductive organ epithelial layers. This was probably due to MRP biocompatibility and its isosmolality (304.33 ± 0.58 mOsm/kg). Furthermore, compared to negative controls, there was no statistically significant increase in pro-inflammatory cytokines such as IL1α, Ilβ, IL7, IP10, and TNFα. Collectively, these data suggest that MRP is a relatively safe nanotemplate for HIV-1 gp120 stimuli responsive vaginal microbicide delivery system." @default.
- W2904652816 created "2018-12-22" @default.
- W2904652816 creator A5011554969 @default.
- W2904652816 creator A5020312661 @default.
- W2904652816 creator A5021029414 @default.
- W2904652816 creator A5033979379 @default.
- W2904652816 creator A5086982063 @default.
- W2904652816 date "2018-12-10" @default.
- W2904652816 modified "2023-09-26" @default.
- W2904652816 title "Preclinical Safety Evaluation of HIV-1 gp120 Responsive Microbicide Delivery System in C57BL/6 Female Mice" @default.
- W2904652816 cites W1498816578 @default.
- W2904652816 cites W1512733937 @default.
- W2904652816 cites W1513911438 @default.
- W2904652816 cites W1625359097 @default.
- W2904652816 cites W1725500992 @default.
- W2904652816 cites W1964827512 @default.
- W2904652816 cites W1965673179 @default.
- W2904652816 cites W1967528194 @default.
- W2904652816 cites W1976749751 @default.
- W2904652816 cites W1978934985 @default.
- W2904652816 cites W1979148488 @default.
- W2904652816 cites W1983242135 @default.
- W2904652816 cites W1986029856 @default.
- W2904652816 cites W1986797955 @default.
- W2904652816 cites W1988398150 @default.
- W2904652816 cites W1995605444 @default.
- W2904652816 cites W2006217045 @default.
- W2904652816 cites W2006509278 @default.
- W2904652816 cites W2010216650 @default.
- W2904652816 cites W2019320607 @default.
- W2904652816 cites W2022454292 @default.
- W2904652816 cites W2022483210 @default.
- W2904652816 cites W2023485889 @default.
- W2904652816 cites W2029329186 @default.
- W2904652816 cites W2029518347 @default.
- W2904652816 cites W2037616829 @default.
- W2904652816 cites W2040352436 @default.
- W2904652816 cites W2044626782 @default.
- W2904652816 cites W2047154690 @default.
- W2904652816 cites W2050937329 @default.
- W2904652816 cites W2056981225 @default.
- W2904652816 cites W2057972471 @default.
- W2904652816 cites W2063353079 @default.
- W2904652816 cites W2064556230 @default.
- W2904652816 cites W2075414471 @default.
- W2904652816 cites W2080263385 @default.
- W2904652816 cites W2085371090 @default.
- W2904652816 cites W2090209293 @default.
- W2904652816 cites W2094312047 @default.
- W2904652816 cites W2096790979 @default.
- W2904652816 cites W2112589439 @default.
- W2904652816 cites W2112792923 @default.
- W2904652816 cites W2113052440 @default.
- W2904652816 cites W2113659812 @default.
- W2904652816 cites W2114721577 @default.
- W2904652816 cites W2138170968 @default.
- W2904652816 cites W2139642740 @default.
- W2904652816 cites W2145273953 @default.
- W2904652816 cites W2146939936 @default.
- W2904652816 cites W2150924565 @default.
- W2904652816 cites W2156631886 @default.
- W2904652816 cites W2157643616 @default.
- W2904652816 cites W2159468612 @default.
- W2904652816 cites W2159741426 @default.
- W2904652816 cites W2163119252 @default.
- W2904652816 cites W2166192929 @default.
- W2904652816 cites W2166468321 @default.
- W2904652816 cites W2170961658 @default.
- W2904652816 cites W2183083845 @default.
- W2904652816 cites W2199808155 @default.
- W2904652816 cites W2230115113 @default.
- W2904652816 cites W2290638097 @default.
- W2904652816 cites W2320589260 @default.
- W2904652816 cites W2412497043 @default.
- W2904652816 cites W2489298732 @default.
- W2904652816 cites W2528451823 @default.
- W2904652816 cites W2528979240 @default.
- W2904652816 cites W2543005760 @default.
- W2904652816 cites W2562832572 @default.
- W2904652816 cites W2581870034 @default.
- W2904652816 cites W2604923378 @default.
- W2904652816 cites W2606311710 @default.
- W2904652816 cites W2615187673 @default.
- W2904652816 cites W2626692807 @default.
- W2904652816 cites W2749028747 @default.
- W2904652816 cites W2767508353 @default.
- W2904652816 cites W2776545664 @default.
- W2904652816 cites W2805419235 @default.
- W2904652816 cites W4300101793 @default.
- W2904652816 cites W589407763 @default.
- W2904652816 doi "https://doi.org/10.1021/acs.molpharmaceut.8b00872" @default.
- W2904652816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30525661" @default.
- W2904652816 hasPublicationYear "2018" @default.
- W2904652816 type Work @default.
- W2904652816 sameAs 2904652816 @default.
- W2904652816 citedByCount "1" @default.
- W2904652816 countsByYear W29046528162022 @default.
- W2904652816 crossrefType "journal-article" @default.